Viking Therapeutics (VKTX) Cash & Equivalents (2014 - 2026)

Viking Therapeutics has reported Cash & Equivalents for 13 years, with the latest figure at $125.8 million in Q2 2026.

• Quarterly Cash & Equivalents rose 271.16% year-over-year to $125.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $125.8 million (up 271.16% YoY) and the FY2025 annual result came in at $165.8 million, up 521.57% from the prior year.
• Cash & Equivalents climbed to $125.8 million in Q2 2026 per VKTX's latest filing, from $118.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $195.6 million in Q1 2024 and troughed at $18.4 million in Q1 2023.
• A 5-year average of $82.0 million and a median of $52.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 1629.43% in 2022, then slumped 89.72% in 2023.
• Over 5 years, Cash & Equivalents stood at $36.6 million in 2022, then jumped by 51.55% to $55.5 million in 2023, then plunged by 51.95% to $26.7 million in 2024, then surged by 521.57% to $165.8 million in 2025, then retreated by 24.16% to $125.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $125.8 million, $118.1 million, and $165.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.